Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin ® ) in paediatric patients under 6 years of age with severe von Willebrand disease

Plasma-derived von Willebrand factor (VWF) (Wilfactin , LFB, France) was developed for prophylaxis and treatment of haemorrhages in both adults and adolescents with von Willebrand disease (VWD). Replacement therapy in paediatric patients is a key element of the clinical trial programme. Patients age...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood transfusion = Trasfusione del sangue 2023-01, Vol.21 (1), p.83-92
Hauptverfasser:	Gouider, Emna, Klukowska, Anna, Maes, Philip, Platokouki, Helen, Pujol, Sonia, Henriet, Céline, Bridey, Françoise, Goudemand, Jenny
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anaphylaxis - chemically induced Child Factor VIII - adverse effects Hemorrhage - chemically induced Hemorrhage - drug therapy Hemorrhage - prevention & control Hemostasis and Thrombosis: Original article Hemostatics - adverse effects Humans von Willebrand Diseases - drug therapy von Willebrand Factor - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Plasma-derived von Willebrand factor (VWF) (Wilfactin , LFB, France) was developed for prophylaxis and treatment of haemorrhages in both adults and adolescents with von Willebrand disease (VWD). Replacement therapy in paediatric patients is a key element of the clinical trial programme. Patients aged
ISSN:	1723-2007 2385-2070
DOI:	10.2450/2022.0329-21